HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
Evaluation of the immune response of individuals exposed to human immunodeficiency virus (HIV) is an important component of any plan designed to lead toward the development of an AIDS vaccine. Since the levels of antibodies to HIV p17 and the synthetic p17 peptide HGP-30 correlate with stages of pro...
Na minha lista:
| Publicado no: | Proc Natl Acad Sci U S A |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
National Academy of Sciences
1990
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC54679/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1698289/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.87.18.7045 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
